<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate plasma levels of markers of platelet, endothelial cell and blood coagulation activation in <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> patients with or without <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) and to compare them to those found in patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: 42 patients with <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> (35 lepromatous and 7 borderline): 29 aPL(+) and 13 aPL(-), as well as 26 healthy subjects as <z:mpath ids='MPATH_458'>normal</z:mpath> controls (NC) and 79 control aPL patients without <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> (59 with and 20 without APS) were included in the study </plain></SENT>
<SENT sid="2" pm="."><plain>Plasma soluble P and E selectin (sPsel and sEsel), and VCAM-1 (sVCAM-1), prothrombin F1 + 2 fragment (F1 + 2), thrombin-antithrombin complexes (TAT) and D dimer (DD) were measured by ELISA </plain></SENT>
<SENT sid="3" pm="."><plain>The protein C pathway was assessed by the ProC global test </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">Leprosy</z:e> patients with aPL presented increased median levels of sPsel [ng/ml (82.0 vs 36.0, p &lt; 0.001)] and sVCAM-1 [ng/ml (495 vs 335, p &lt; 0.001)] compared to NC, as observed in control aPL patients without <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Levels of sPsel in aPL(+) patients with <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> were significantly higher than in aPL(-) ones (52.5 ng/ml), p = 0.005 </plain></SENT>
<SENT sid="6" pm="."><plain>However, plasma markers of thrombin generation were increased in control aPL patients without <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> but not in those with <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>ProcC global test was abnormal in 24.1% of <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> patients with aPL compared to 4.4% of NC (p &lt; 0.024), and to 57.2% of control patients with aPL without <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> (p = 0.005) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: We demonstrated that although patients with <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> present a high prevalence of aPL, and platelet and endothelial cell activation in vivo to the same extent than patients with APS, they do not show a procoagulant state </plain></SENT>
</text></document>